These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22914601)

  • 1. Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease.
    Shen PC; He LQ; Yang XJ; Cao HX
    J Investig Med; 2012 Oct; 60(7):1041-7. PubMed ID: 22914601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Losartan and enalapril are comparable in reducing proteinuria in children.
    Webb NJ; Shahinfar S; Wells TG; Massaad R; Gleim GW; Santoro EP; Sisk CM; Lam C
    Kidney Int; 2012 Oct; 82(7):819-26. PubMed ID: 22739977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
    Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
    Guo LL; Pan Y; Jin HM
    Nephrol Dial Transplant; 2009 Jun; 24(6):1876-83. PubMed ID: 19164322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders.
    Ellis D; Moritz ML; Vats A; Janosky JE
    Am J Hypertens; 2004 Oct; 17(10):928-35. PubMed ID: 15485756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.
    Horita Y; Tadokoro M; Taura K; Suyama N; Taguchi T; Miyazaki M; Kohno S
    Hypertens Res; 2004 Dec; 27(12):963-70. PubMed ID: 15894837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.
    Lin SL; Chen YM; Chiang WC; Wu KD; Tsai TJ
    Am J Kidney Dis; 2008 Sep; 52(3):464-74. PubMed ID: 18617301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.
    Hou FF; Xie D; Zhang X; Chen PY; Zhang WR; Liang M; Guo ZJ; Jiang JP
    J Am Soc Nephrol; 2007 Jun; 18(6):1889-98. PubMed ID: 17494885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aliskiren and losartan trial in non-diabetic chronic kidney disease.
    Woo KT; Choong HL; Wong KS; Tan HK; Foo M; Fook-Chong S; Lee EJ; Anantharaman V; Lee GS; Chan CM
    J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):515-22. PubMed ID: 24742970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?
    Weldegiorgis M; de Zeeuw D; Dwyer JP; Mol P; Heerspink HJL
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1595-1600. PubMed ID: 28923834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T;
    Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal and retinal effects of enalapril and losartan in type 1 diabetes.
    Mauer M; Zinman B; Gardiner R; Suissa S; Sinaiko A; Strand T; Drummond K; Donnelly S; Goodyer P; Gubler MC; Klein R
    N Engl J Med; 2009 Jul; 361(1):40-51. PubMed ID: 19571282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial.
    Kim JY; Son JW; Park S; Yoo TH; Kim YJ; Ryu DR; Chin HJ
    Trials; 2017 Dec; 18(1):632. PubMed ID: 29284530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome.
    Webb NJ; Shahinfar S; Wells TG; Massaad R; Gleim GW; McCrary Sisk C; Lam C
    Pediatr Nephrol; 2013 May; 28(5):737-43. PubMed ID: 23207876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, controlled study of losartan in children with proteinuria.
    Webb NJ; Lam C; Loeys T; Shahinfar S; Strehlau J; Wells TG; Santoro E; Manas D; Gleim GW
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):417-24. PubMed ID: 20089489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan.
    Ito S; Naritomi H; Ogihara T; Shimada K; Shimamoto K; Tanaka H; Yoshiike N
    Hypertens Res; 2012 Aug; 35(8):867-73. PubMed ID: 22573200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aliskiren combined with losartan in type 2 diabetes and nephropathy.
    Parving HH; Persson F; Lewis JB; Lewis EJ; Hollenberg NK;
    N Engl J Med; 2008 Jun; 358(23):2433-46. PubMed ID: 18525041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.
    Saito I; Kushiro T; Zenimura N; Matsushita Y; Sagawa K; Hiramatsu K; Yamaguchi F
    J Nephrol; 2012; 25(5):699-708. PubMed ID: 22020401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renoprotect and blood pressure lowering effect of low-dose hydrochlorothiazide added to intensive renin-angiotensin inhibition in hypertensive patients with chronic kidney disease.
    Abe M; Okada K; Maruyama T; Matsumoto K
    Int J Clin Pharmacol Ther; 2009 Aug; 47(8):525-32. PubMed ID: 19640361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.